Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPGL008 in advanced malignant tumors
NCT07038005Phase 1Recruiting
- Sponsor
- 3SBio
- Start
- Jul 2025
- Primary completion
- Sep 2026
- Modality
- Biological product
- Countries
- 1
01
Overview
Phase 1, open-label trial of SPGL008 in cancer, sponsored by 3SBio. Primary endpoints: Dose Limiting Toxicity at 21 days and Maximum tolerated dose at 21 days. Started Jul 2025; status: recruiting.
02
Drugs
SPGL008
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07038005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038005.